Human IFN-gamma Antibody Summary
Gln24-Gln166
Accession # AAP20098.1
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
Detection of IFN- gamma in Human PBMCs by Flow Cytometry. Human peripheral blood mononuclear cells (PBMCs) treated with 50 ng/mL PMA, 1 ug/mL Ionomycin, and 3 uM Monensin overnight were stained with either (A) Mouse Anti-Human IFN- gamma Monoclonal Antibody (Catalog # MAB2851) or (B) Mouse IgG2B Isotype Control (Catalog # MAB0041) followed by anti-Mouse IgG PE-conjugated secondary antibody (Catalog # F0102B) and Mouse Anti-Human CD3 epsilon APC-conjugated Monoclonal Antibody (Catalog # FAB100A). To facilitate intracellular staining, cells were fixed and permeabilized with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012). View our protocol for Staining Intracellular Molecules.
IFN‑ gamma Inhibition of EMCV-induced Cytopathy and Neutralization by Human IFN‑ gamma Antibody. Recombinant Human IFN-gamma (Catalog # 285-IF) reduces the Encephalomyocarditis Virus (EMCV)-induced cytopathy in the HeLa human cervical epithelial carcinoma cell line in a dose-dependent manner (orange line). Inhibition of EMCV activity elicited by Recombinant Human IFN-gamma (5 ng/mL) is neutralized (green line) by increasing concen-trations of Mouse Anti-Human IFN-gamma Monoclonal Antibody (Catalog # MAB2851). The ND50 is typically 0.2-0.6 µg/mL.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IFN-gamma
Interferon-gamma (IFN-gamma ), also known as type II or immune interferon, exerts a wide range of immunoregulatory activities and is considered to be the prototype proinflammatory cytokine (1, 2). Mature human IFN-gamma exists as a non-covalently linked homodimer of 20-25 kDa variably glycosylated subunits (3). It shares 90% amino acid (aa) sequence identity with rhesus IFN-gamma, 59-64% with bovine, canine, equine, feline, and porcine IFN‑ gamma, and 37-43% with cotton rat, mouse, and rat IFN-gamma. IFN-gamma dimers bind to IFN-gamma RI (alpha subunits) which then interact with IFN-gamma RII (beta subunits) to form the functional receptor complex of two alpha and two beta subunits. Inclusion of IFN-gamma RII increases the binding affinity for ligand and the efficiency of signal transduction (4, 5). IFN-gamma is produced by a variety of immune cells under inflammatory conditions, notably by T cells and NK cells (6). It plays a key role in host defense by promoting the development and activation of Th1 cells, chemoattraction and activation of monocytes and macrophages, upregulation of antigen presentation molecules, and immunoglobulin class switching in B cells. It also exhibits antiviral, antiproliferative, and apoptotic effects (6, 7). In addition, IFN-gamma functions as an anti-inflammatory mediator by promoting the development of regulatory T cells and inhibiting Th17 cell differentiation (8, 9). The pleiotropic effects of IFN-gamma contribute to the development of multiple aspects of atherosclerosis (7).
- Billiau, A. and P. Matthys (2009) Cytokine Growth Factor Rev. 20:97.
- Pestka, S. et al. (2004) Immunol. Rev. 202:8.
- Gray, P.W. and D.V. Goeddel (1982) Nature 298:859.
- Marsters, S.A. et al. (1995) Proc. Natl. Acad. Sci. USA 92:5401.
- Krause, C.D. et al. (2000) J. Biol. Chem. 275:22995.
- Schroder, K. et al. (2004) J. Leukoc. Biol. 75:163.
- McLaren, J.E. and D.P. Ramji (2009) Cytokine Growth Factor Rev. 20:125.
- Muhl, H. and J. Pfeilschifter (2003) Int. Immunopharmacol. 3:1247.
- Kelchtermans, H. et al. (2008) Trends Immunol. 29:479.
Product Datasheets
Citations for Human IFN-gamma Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
7
Citations: Showing 1 - 7
Filter your results:
Filter by:
-
Reverse translation identifies the synergistic role of immune checkpoint blockade and IL-15 to enhance immunotherapy of ovarian cancer
Authors: Martin Felices, Erin Wesley, Laura E. Bendzick, Behiye Kodal, Rachel Hopps, Bartosz Grzywacz et al.
Cancer Immunology Research
-
Adipose tissue specific CCL18 associates with cardiometabolic diseases in non-obese individuals implicating CD4+ T cells
Authors: N Subramania, K Hofwimmer, B Tavira, L Massier, DP Andersson, P Arner, J Laurenciki
Cardiovascular Diabetology, 2023-04-12;22(1):84.
Species: Human
Sample Types: Cell Culture Supernates
Applications: Neutralization -
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls
Authors: N Le Bert, AT Tan, K Kunasegara, CYL Tham, M Hafezi, A Chia, MHY Chng, M Lin, N Tan, M Linster, WN Chia, MI Chen, LF Wang, EE Ooi, S Kalimuddin, PA Tambyah, JG Low, YJ Tan, A Bertoletti
Nature, 2020-07-15;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Human monocyte-derived macrophages inhibit HCMV spread independent of classical antiviral cytokines
Authors: Jennifer Becker, Volker Kinast, Marius Döring, Christoph Lipps, Veronica Duran, Julia Spanier et al.
Virulence
-
Interleukin-16-producing NK cells and T-cells in the blood of tobacco smokers with and without COPD
Authors: Apostolos Bossios
Int J Chron Obstruct Pulmon Dis, 2016-09-15;11(0):2245-2258.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Clinical improvement in chronic plaque-type psoriasis lesions after narrow-band UVB therapy is accompanied by a decrease in the expression of IFN-gamma inducers -- IL-12, IL-18 and IL-23.
Authors: Piskin G, Tursen U, Sylva-Steenland RM, Bos JD, Teunissen MB
Exp. Dermatol., 2004-12-01;13(12):764-72.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-Fr -
PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer
Authors: J Hong, JH Lee, Z Zhang, Y Wu, M Yang, Y Liao, R de la Rosa, J Scheirer, D Pechacek, N Zhang, Z Xu, T Curiel, X Tan, TH Huang, K Xu
Cancer Research, 2022-12-16;0(0):.
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human IFN-gamma Antibody
Average Rating: 4.5 (Based on 2 Reviews)
Have you used Human IFN-gamma Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by: